Literature DB >> 12376473

Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk.

Andrea Gsur1, Martin Preyer, Gerald Haidinger, Thomas Zidek, Stephan Madersbacher, Georg Schatzl, Michael Marberger, Christian Vutuc, Michael Micksche.   

Abstract

As the development of prostate cancer is androgen-dependent, it has been hypothesized that variation in transcriptional activity by the androgen receptor (AR) related to polymorphic CAG repeats in exon 1, influences prostate cancer risk. The AR regulates gene transcription by binding to androgen-response elements (AREs) in target genes, such as the prostate-specific antigen (PSA). In the ARE-I sequence of the PSA gene an adenine to guanine polymorphism is described. It has been hypothesized that the AR binds the two PSA alleles (A and G) with differing affinities and may, thereby, differentially influence prostate cancer risk. To examine the role of the polymorphisms in the AR and PSA genes in prostate cancer susceptibility, we conducted a case-control study of Austrian Caucasians with 190 newly diagnosed prostate cancer patients and 190 age-matched control men with benign prostatic hyperplasia (BPH). The polymorphisms were determined by polymerase chain reaction (PCR)-based methods using DNA from peripheral white blood cells. Logistic regressions were performed to calculate odds ratios (OR) and confidence limits (CL) and to control for possible confounders. Our data provide no evidence for an association between prostate cancer and CAG repeat length. However, we found a significant influence of the ARE-I PSA polymorphism on prostate cancer risk, when calculating the combination of the A/G and G/G genotypes relative to subjects with the A/A genotype (OR = 0.63; 95% CL 0.39-0.99; P = 0.048), suggesting that the G allele has a protective effect. In a case analysis according to Gleason score, the PSA G/G genotype was significantly more frequent in patients with Gleason score >7 (35.1%) than in patients with Gleason score <7 (21.5%), providing evidence that the PSA G/G genotype is associated with more advanced disease at time of diagnosis. However, the ambivalent role of the PSA during prostate carcinogenesis needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376473     DOI: 10.1093/carcin/23.10.1647

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  16 in total

1.  The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis.

Authors:  Mingliang Gu; Xiaoqun Dong; Xuezhi Zhang; Wenquan Niu
Journal:  Mol Biol Rep       Date:  2011-06-12       Impact factor: 2.316

2.  Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer.

Authors:  Xueying Mao; Jie Li; Xingxing Xu; Lara K Boyd; Weiyang He; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Guangwen Cao; Daniel Berney; Guosheng Ren; Xin Gou; Hongwei Zhang; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

3.  Are GSTM1, GSTT1 and CAG repeat length of androgen receptor gene polymorphisms associated with risk of prostate cancer in Iranian patients?

Authors:  Zahra Ousati Ashtiani; Sayed-Mohammad Hasheminasab; Mohsen Ayati; Bareto Sabah Goulian; Mohammad Hossein Modarressi
Journal:  Pathol Oncol Res       Date:  2010-11-19       Impact factor: 3.201

4.  Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population.

Authors:  Monika Kmetová Sivoňová; Dušan Dobrota; Róbert Dušenka; Iveta Waczulíková; Peter Slezák; Tatiana Matáková; Silvia Mahmoodová; Dušan Mištuna; Ján Kliment
Journal:  Mol Biol Rep       Date:  2012-04-22       Impact factor: 2.316

5.  Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study.

Authors:  Matthew L Freedman; Celeste L Pearce; Kathryn L Penney; Joel N Hirschhorn; Laurence N Kolonel; Brian E Henderson; David Altshuler
Journal:  Am J Hum Genet       Date:  2004-11-29       Impact factor: 11.025

6.  Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer.

Authors:  Scott D Cramer; Jielin Sun; S Lilly Zheng; Jianfeng Xu; Donna M Peehl
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

7.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

8.  Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.

Authors:  Fredrik Wiklund; S Lilly Zheng; Jielin Sun; Hans-Olov Adami; Hans Lilja; Fang-Chi Hsu; Pär Stattin; Jan Adolfsson; Scott D Cramer; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Henrik Grönberg; Jianfeng Xu
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

Review 9.  Genetic polymorphisms and prostate cancer risk.

Authors:  Andrea Gsur; Elisabeth Feik; Stephan Madersbacher
Journal:  World J Urol       Date:  2003-11-26       Impact factor: 4.226

10.  Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels.

Authors:  C Jesser; L Mucci; D Farmer; C Moon; H Li; J M Gaziano; M Stampfer; J Ma; P Kantoff
Journal:  Br J Cancer       Date:  2008-09-30       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.